“Patients with heFH are difficult to treat in clinical practice. The actual recommended treatment for this category of patients is a statin at the maximum tolerated dose (mainly atorvastatin or rosuvastatin) and if necessary, combination with other lipid-lowering drugs. However, even at this maximum tolerated treatment, their baseline levels of LDL-C in our studies were relatively high (mean around 3.5 and 3.7mmol/l),” he said.
“It is important to emphasize that in both trials, patients were very well treated before the trial,” noted Dr. Farnier. All of them were on statins, with more than 80% on maximum doses, and 55-65% on combination therapy with ezetimibe.”
“Previous studies have shown that only about 20% of heFH patients are able to reach a goal of less than 2.5mmol/l.” noted Dr. Farnier. “Due to the dramatic complementary decrease in LDL-C that our studies obtained with alirocumab, this new strategy is particularly important for this category of patients at high risk of cardiovascular disease.”
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved